Αρχική World News Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and Positive...

Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and Positive Results on MRI Non-inferior to Standard Biopsy

In a study of population-based screening by invitation, the results showed that among men with elevated PSA levels, combined biopsy performed only in men who had positive results on magnetic resonance imaging (MRI) was non-inferior to standard biopsy for detecting clinically significant prostate cancer. The markedly reduced incidences of unnecessary biopsy and diagnosis of clinically insignificant cancer address key barriers impeding implementation of population-based screening for prostate cancer.

The reduced biopsy rate and potential downstream savings that result from less overtreatment offer potential cost savings that may offset the additional costs of MRI according to STHLM3-MRI researchers, who presented the findings at the 36th Annual Congress of the European Association of Urology (8-12 July 2021) and published simultaneously in The New England Journal of Medicine.

The authors wrote in the study background that prostate cancer screening in which PSA testing is followed by standard ultrasound-guided, transrectal prostate biopsy in men with elevated PSA levels reduces prostate cancer mortality. However, PSA-based screening also leads to high rates of overdiagnosis and overtreatment of clinically insignificant prostate cancer and to many unnecessary biopsies. MRI-directed biopsy has shown the potential to address this challenge, but the implications of its use in the context of organised prostate cancer screening are unknown.

The STHLM3-MRI study compared several different screening strategies that used combinations of risk prediction, MRI-directed biopsy, and standard biopsy in a population-based, organised screening by invitation design. 

The study team invited men between 50 and 74 years of age from the general population to participate; those with PSA levels of 3 ng per milliliter or higher were randomly assigned in a 2:3 ratio to undergo a standard biopsy or MRI-directed and standard biopsy if the MRI results suggested prostate cancer. The primary outcome was the proportion of men in the intention-to-treat (ITT) population in whom clinically significant cancer with a Gleason score ≥7 was diagnosed. A key secondary outcome was the detection of clinically insignificant cancers in case of Gleason score 6.

Among 12,750 enrolled men, 1532 had elevated PSA and were randomly assigned to undergo biopsy. In particular, 603 were assigned to the standard biopsy and 929 to combined MRI-directed and standard biopsy.

In the ITT analysis, clinically significant cancer was diagnosed in 192 men (21%) in the combined biopsy group, as compared with 106 men (18%) in the standard biopsy group (difference 3 percentage points; 95% confidence interval [CI] −1 to 7; p < 0.001 for non-inferiority).

The percentage of clinically insignificant cancers was lower in the combined biopsy group than in the standard biopsy group, 41 men (4%) versus 73 men (12%) with difference of −8 percentage points (95% CI −11 to −5).

The authors commented when normalised to a population of 10,000 men between 50 and 74 years of age, in which those with elevated PSA levels are referred for biopsy, the combined biopsy approach in men with positive MRI scans would result in 409 fewer men undergoing biopsy, 366 fewer biopsies with benign findings, and 88 fewer clinically insignificant cancers detected than with the standard biopsy approach. These numbers represent 48%, 73%, and 62% lower incidences, respectively, with the use of MRI and the combined biopsy approach.

In conclusion, population-based screening showed that men over age 50 with elevated PSA and negative MRI results could safely forgo biopsy. Detection of clinically significant cancer among men with positive MRI results who underwent MRI-directed and standard biopsies was similar to that in the standard biopsy group, but the MRI group had fewer findings of clinically insignificant cancers. 

The study was supported by the Swedish Research Council, the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer (StratCan) at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, and Swedish e-Science Research Center, Karolinska Institutet, and the Swedish Prostate Cancer Foundation.

Reference

Eklund M, Jäderling F, Discacciati A, et al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. NEJM; Published online 9 July 2021. DOI: 10.1056/NEJMoa2100852

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...